Related Experiment Video

Updated: Jul 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic viruses: what's next?

John C Bell1

  • 1Ottawa Health Research Institute, 503 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada. jbell@ohri.ca

Current Cancer Drug Targets
|March 10, 2007
PubMed

Insights

Oncolytic viruses (OVs) are a promising new cancer therapy. This article explores how OVs can revolutionize cancer treatment by targeting tumors in multiple ways, improving success rates.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Cancer's complexity and adaptability pose significant treatment challenges.
  • Current cancer therapies face limitations due to tumor evolution.
  • There is a need for innovative therapeutic strategies to improve cancer treatment outcomes.

Purpose of the Study:

  • To propose Oncolytic Viruses (OVs) as a new generation of smart therapeutics for cancer.
  • To highlight the potential of OVs to revolutionize cancer management.
  • To discuss the future development and applications of the OV platform.

Main Methods:

  • Review of current understanding of cancer's molecular biology.
  • Exploration of the OV platform's potential.
  • Speculation on future directions in OV development.

Main Results:

  • Oncolytic Viruses (OVs) demonstrate significant potential as targeted cancer therapeutics.
  • The OV platform offers a multi-pronged approach to combat cancer's adaptability.
  • Embracing OV technology is crucial for advancing cancer treatment.

Conclusions:

  • Oncolytic Viruses represent a powerful new tool in the fight against cancer.
  • Further development and application of OV technology are essential for improving patient outcomes.
  • The integration of molecular cancer biology with OV platforms promises future breakthroughs.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...